Gravity Analytica

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

INKT 12.18.2024

SERA-AI Powered Highlights

Drug:unknown-unknown agenT-797

Diseases:refractory gastric cancer

Date of Upcoming Event:2025-01-23

Name of Upcoming Event:American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium

Full Press Release SEC Filings Our INKT Tweets

About Gravity Analytica

Recent Filings

PDF Version

Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer

NEW YORK,Dec. 18, 2024(GLOBE NEWSWIRE) --MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcomingAmerican Society of Clinical Oncology Gastrointestinal Cancers(ASCO GI) Symposium that will take place onJanuary 23-25, 2025, inSan Francisco, California. The poster presentation will highlight the ongoing Phase 2 study of agenT-797 in combination with Agenus’ botensilimab/balstilimab in patients with refractory gastric cancer.

Presentation Details

Abstract Title:A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinomaAbstract Number:TPS515Presenting Author:Dr.Samuel CytrynSession:Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal CancersSession Date and Time:1/23/2025,11:30 AM-1:00 PM

Complete abstracts will be released at5:00 PM ETonJanuary 21^st, 2025. Data presented at the conference will be available to view in the publications section of the MiNK website (https://minktherapeutics.com/publications/) following the ASCO GI Meeting.

AboutMiNK Therapeutics

MiNK Therapeuticsis a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered inNew York, NY. For more information, visithttps://minktherapeutics.com/or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with theSEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact917-362-1370investor@minktherapeutics.com

Media Contact781-674-4428communications@minktherapeutics.com

Source: MiNK Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com